A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.

Analysis of the effect in MYCN amplified and nonamplified tumor subgroups (Figure 1D‐G ) shows a trend toward improved EFS and OS in both groups at 5 years, although most comparisons did not reach statistical significance.

also in 111,027 other papers